Glaucoma treatment in the blink of an eye

The LiGHT trial has had an astounding impact on how we view lasers in glaucoma treatment since its first publication in 2019.1 This is because the trial showed better clinical outcomes when treating patients with selective laser trabeculoplasty (SLT) than with topical medication as an initial treatment for people with ocular hypertension or open angle glaucoma. Since then, and for the first time ever, the 2020 European Glaucoma Society’s (EGS) Guidelines have recommended the use of lasers as a first-line treatment option.2 With the many challenges associated with medication, relating to adherence to an ongoing management plan and patient compliance with drops, the use of laser can offer better patient outcomes for glaucoma and ocular hypertension in routine practice.